1 unced for neutral and polar amino acids, and glycosuria.

2 cative of Fanconi syndrome, characterized by glycosuria, aminoaciduria, calciuria, and albuminuria.

3 t high risk of death and 2 new risk markers, glycosuria and hemoglobin decline.

4 is the underlying mechanism for the observed glycosuria and improved glucose tolerance in ArcPOMC-def

5 e and chronic empagliflozin treatment caused glycosuria during fasting (median, 7.8 [interquartile ra

6                    Pharmacologically induced glycosuria elicits adaptive responses in glucose homeost

7 o pharmacologically induced acute or chronic glycosuria has not been investigated in human diabetes.

8 tio, 3.5; 95% confidence interval, 2.4-5.1); glycosuria (hazard ratio, 4.2; confidence interval, 1.3-

9  with type 2 diabetes, empagliflozin-induced glycosuria improved beta cell function and insulin sensi

10 e following: tubular proteinuria, euglycemic glycosuria, increased urinary phosphate, and uric acid e

11                               The pattern of glycosuria-induced changes was similar in subjects witho

12                                          The glycosuria of ArcPOMC-deficient mice was due to decrease

13 reased glucose effectiveness and exaggerated glycosuria relative to wild-type littermate controls at

14 s of carbohydrate into urine, SGLT2-mediated glycosuria results in a progressive shift in fuel utiliz

15 ecular weight proteinuria, aminoaciduria and glycosuria, together with rickets in some patients.

16 uced in the setting of hyperglycemia-induced glycosuria, were lower in black persons than in white pe

17 eversed alterations in glucose tolerance and glycosuria, whereas, conversely, administration of the a